Canilang, Baby Boy .
HRN: 25-29-31 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/23/2024
CEFOTAXIME 500MG (VIAL)
06/23/2024
06/30/2024
IV
125 Mg
Q 12
T/C Neonatal Sepsis
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes